Acadia Pharmaceuticals appoints Jonathan M. Poole to Board of Directors

ACADIA PHARMACEUTICALS INC

Poole appointed effective March 3, 2026 as Class II director, term expiring at 2027 annual meeting.
He will serve on the Audit Committee; receives $50k annual cash retainer plus $12.5k for committee role.
Initial equity grant with $200k target fair value (split options/RSUs); prorated annual grant of $95,300.
Future annual equity grants of $400k (half options, half RSUs) with quarterly vesting over one year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.